E-TACE with donafenib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that cannot be removed with surgery.
- You are between 18 and 80 years old.
- Your cancer is at a specific stage (Ib, IIa, IIb, IIIa, IIIb or A, B, C).
- You have not had certain previous treatments like TACE, targeted drugs, or immunotherapy.
- Your liver and kidney function are good enough (based on blood tests).
- You are in good overall health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a new combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) for people with advanced liver cancer that got worse after initial treatment with immunotherapy. The goal is to see if this 'rechallenge' approach can help control the cancer again.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.